Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 19 mutations

Tyrosine kinase inhibitors (TKIs) are used to treat non-small cell lung cancers (NSCLC) driven by epidermal growth factor receptor (EGFR) mutations in the tyrosine kinase domain (TKD). TKI responses vary across tumors driven by the heterogeneous group of exon 19 deletions and mutations, but the mole...

Descripción completa

Detalles Bibliográficos
Autores principales: van Alderwerelt van Rosenburgh, Iris K., Lu, David M., Grant, Michael J., Stayrook, Steven E., Phadke, Manali, Walther, Zenta, Goldberg, Sarah B., Politi, Katerina, Lemmon, Mark A., Ashtekar, Kumar D., Tsutsui, Yuko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9649653/
https://www.ncbi.nlm.nih.gov/pubmed/36357385
http://dx.doi.org/10.1038/s41467-022-34398-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9649653/
https://www.ncbi.nlm.nih.gov/pubmed/36357385
http://dx.doi.org/10.1038/s41467-022-34398-z

Ejemplares similares